Observational registry following adults with neuromyelitis optica spectrum disorder
Follows adults with neuromyelitis optica spectrum disorder under specialist neurology care over time.
Plain-language title generated from the registry record
Registry title: CorEvitas SPHERES (Synergy of Prospective Health & Experimental Research for Emerging Solutions) Registry for Neuromyelitis Optica Spectrum Disorder (NMOSD)
Key facts
- Where
- Waltham, United StatesSee the site
Where in United States
- CorEvitas, LLCWaltham, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- CorEvitas
- Trial code
- NCT04886492
- Record updated
- 9 February 2026
- Original description
This is a Prospective, observational research study for patients with NMOSD under the care of a licensed neurologist. Approximately 800 patients and 35 clinical sites in North America will be recruited to participate with no defined upper limit for either target.Read full original descriptionShow less
CorEvitas SPHERES (Synergy of Prospective Health & Experimental Research for Emerging Solutions) Registry for Neuromyelitis Optica Spectrum Disorder (NMOSD)
This is a Prospective, observational research study for patients with NMOSD under the care of a licensed neurologist. Approximately 800 patients and 35 clinical sites in North America will be recruited to participate with no defined upper limit for either target.
Inclusion: Has a diagnosis of NMOSD at the time of enrollment according to the 2015 IPND consensus diagnostic criteria for NMOSD†; Age 18 years or older at the time of enrollment; Willing to provide Personal Information.
Exclusion: Has had a clinically confirmed NMOSD neuro-episode within the 12 weeks prior to enrollment; Is participating or planning to participate in a double-blind randomized trial for an NMOSD drug. Note: Concurrent participation in another observational registry or open-label Phase 3b/4 trial is allowed; All serology types (APQ4 +/- and MOG +/-) are eligible to enroll in the registry given they meet the 2015 IPND diagnostic criteria.